Skip to main content
Search

# Rosalind

2 related articles

Subscribe to updates
  1. Fewer refusals on dual-use biology, but GPT-Rosalind-6 ships only to vetted labs

    GPT-Rosalind-6 is a frontier reasoning model for biology, drug discovery and translational medicine, offered as GPT-Rosalind-6 Research only to qualified scientists, research institutes, companies and government partners. It uses the same weights as the flagship reasoning model GPT-6 Astra, refuses fewer dual-use biological queries while still refusing biological weaponization and retaining refusals on other safety topics. Under the Preparedness Framework the launch is rated High capability in the Biological and Chemical domain, below the Critical threshold, Critical in Cybersecurity and below High in AI Self-Improvement.

  2. OpenAI News

    OpenAI buys Orchestra Bio for Rosalind: agents take over trial tracking so drug teams can decide

    OpenAI has acquired Orchestra Bio, a platform that helps biopharma teams coordinate drug development, and is combining its team and technology with Rosalind, OpenAI's AI models and tools for life sciences research. A new medicine takes roughly 10 to 15 years on average from target discovery to US regulatory approval, and teams must orchestrate programs across internal departments and external partners, often relying on disconnected systems. The stated aim is to build agents that connect scientific findings with the studies, decisions and next steps needed to advance a potential medicine.

You’re all caught up